The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) whose disease progressed after chemotherapy. The FDA has approved ...

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant.

Sunvozertinib received FDA priority review for NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy progression. The WU-KONG1 Part B study showed a 53.3% objective response ...

Abenacianine, a fluorescent imaging agent, aids in real-time tumor visualization during lung cancer surgeries, enhancing surgical precision and outcomes. Fast track designation by the FDA highlights ...

The occurrence of NSCLC is not uncommon among never-smokers. These patients are more likely to be young, female, symptomatic at the time of presentation, have poorly differentiated tumors, and ...

Background: Ki-67 expression is a well-established prognostic marker in various cancers. However, Ki-67 expression is also known as being heterogeneous. We investigated the prognostic significance ...

This decision follows the FDA’s earlier Breakthrough Therapy Designations for Sunvozertinib in treatment naïve and relapsed or refractory settings. Currently, no small molecule drug has been approved ...

BROOKSVILLE, Fla., Jan. 9, 2025 /PRNewswire/ -- American Injectables, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, is proud to announce it has ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain ...

If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib's NDA was submitted ...